POXEL.PA Poxel S.A. EURONEXT 04 Feb 2026: -17.19% intraday, support near €0.31

POXEL.PA stock plunged -17.19% intraday to €0.316 on EURONEXT on 04 Feb 2026 as trading volume rose to 393,146 shares. The move pushed price well below the previous close of €0.38 and set a day low at €0.308. Investors reacted to weak near-term momentum in the biotech sector and thin market capitalisation of €18,684,376.00. We examine what drove the selloff, how fundamentals and technicals line up, and what price scenarios traders and holders should monitor next.

POXEL.PA stock intraday price action

Shares of Poxel S.A. (POXEL.PA) fell to a day low of €0.308 after opening at €0.34 and trading as high as €0.3495. The intraday decline of -17.19% corresponds to a change of -€0.0655 versus the previous close of €0.381. Volume at 393,146 shares exceeded the 50-day average volume of 283,690, signalling higher-than-normal selling pressure in Europe’s EURONEXT session.

Catalysts and market context behind the drop

There is no single company press release explaining today’s fall. The biotech sector has shown mixed performance year-to-date and macro commodity and risk flows affected small caps. Broader European risk tone shifted after commodity news and market rotations today; see the commodity update on Investing.com for context source. Peer comparisons on Investing.com show Poxel trailing larger biotech peers on liquidity and market-cap metrics source.

Fundamentals, valuation and earnings context

Poxel reports EPS -0.26 and a negative PE of -1.34, reflecting persistent losses as a clinical-stage biotech. Market cap stands at €18,684,376.00 with 53,690,737 shares outstanding. Key ratios show a price-to-sales of 2.44, current ratio 0.78, and enterprise value to sales 11.07. Research and development represents 17.72% of revenue per recent TTM figures, underscoring cash burn risk ahead of anticipated earnings news on 25 Mar 2026.

Technicals, volume and short-term support levels

Short-term technicals show RSI 56.49, MACD roughly flat and Bollinger mid at €0.24. Intraday support clustered near €0.31 and stronger support near the 50-day average €0.25. Immediate resistance lies at €0.35 and the 200-day average €0.39. On-chain volume indicators and a relative volume of 1.03 suggest the move is tradable but volatile for small-cap biotech listings on EURONEXT.

Meyka AI rates POXEL.PA with a score out of 100

Meyka AI rates POXEL.PA with a score of 60.87 / 100 and assigns a Grade B (HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating on third-party screens shows a recent D+ rating, highlighting fundamental weaknesses. Investors should weigh the Meyka grade against clinical readouts and funding runway.

Price targets, Meyka forecast and scenari os

Meyka AI’s forecast model projects a yearly price of €0.2642, implying -16.27% versus the current €0.316. By scenario: conservative downside target €0.20, base case €0.30, and upside case €0.54 (quarterly model). Forecasts are model-based projections and not guarantees. Traders should monitor cash metrics, upcoming earnings on 25 Mar 2026, and clinical updates that can swing valuation rapidly.

Final Thoughts

POXEL.PA stock moved sharply lower in intraday trading on EURONEXT, dropping -17.19% to €0.316 on unusually high volume. The immediate takeaway is that liquidity and clinical-stage risk drive heightened volatility in this biotech name. Fundamentals show negative EPS -0.26, low current ratio 0.78, and an enterprise value to sales of 11.07, which together highlight funding and execution risk. Meyka AI’s forecast model projects €0.2642 for the year, implying a -16.27% downside from today’s price, while an alternative short-term model points to a possible rebound above €0.54 if clinical or licensing news arrives. Meyka AI rates POXEL.PA 60.87 / 100 (Grade B, HOLD) reflecting mixed prospects against sector peers. For holders, watch €0.31 support and upcoming news flow; for short-term traders, use tight risk controls given low market cap and high intraday swings. Forecasts are model-based projections and not guarantees. For ongoing updates, see Poxel’s page on Meyka AI: Poxel on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.